The Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) decided on April 13 that a pause in administrating the Johnson & Johnson vaccine will do well, especially after six women experienced severe blood clots and one of them lost her life.
Therefore, this decision was taken out of an abundance of caution, as they needed to investigate the rare cases reported in women aged 50 years old or younger, in the United States. However, it’s worth mentioning that more than 6.8 million Americans have already taken the vaccine, which includes one dose, compared to Pfizer and Moderna that require two.
It’s also important to note that blood clotting is very rare, so there’s less than a one in a million chance of developing this severe condition after the COVID-19 vaccination. Another vaccine that also recorded blood clots among patients is the AstraZeneca one, which is not available in the United States just yet.
However, the CDC and FDA announced on April 23, just 11 days after the initial pause, that the Johnson & Johnson vaccine is safe and effective, as the risks are outweighed by the benefits, so the vaccine will continue to be administered in the United States.
Just three days after their announcement, more than half of states have already started to administrate the Jenssen vaccine. But until going on to the states that started using the Jenssen vaccine again, it’s important that people understand everything there is to know about this vaccine.
Make sure to also check: What You Shouldn’t Eat Before COVID-19 Vaccination, According To Study.
Leave a Reply